Evaluation of supervised machine learning algorithms in predicting the poor anticoagulation control and stable weekly doses of warfarin

Sridharan, Kannan; Ramanathan, Murali; Banna, Rashed Al

doi:10.1007/s11096-022-01471-y

Cited by 7 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removing duplicated articles, 3,346 studies were screened by the title and/or abstract, 3,175 irrelevant studies were excluded and 171 articles were included for full‐text review. Finally, 64 articles related to precision dosing using ML were included for analysis 11–74 . The PRISMA flow diagram representing the study selection process and review results is presented in Figure .…”

Section: Resultsmentioning

confidence: 99%

Machine Learning: A New Approach for Dose Individualization

Li,

Tang,

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The application of machine learning (ML) has shown promising results in precision medicine due to its exceptional performance in dealing with complex multidimensional data. However, using ML for individualized dosing of medicines is still in its early stage, meriting further exploration. A systematic review of study designs and modeling details of using ML for individualized dosing of different drugs was performed. We have summarized the status of the study populations, predictive targets, and data sources for ML modeling, the selection of ML algorithms and features, and the evaluation and validation of their predictive performance. We also used the Prediction model Risk of Bias Assessment Tool (PROBAST) to assess the risk of bias of included studies. Currently, ML can be used for both a priori and a posteriori dose selection and optimization, and it can also assist the implementation of therapeutic drug monitoring. However, studies are mainly focused on drugs with narrow therapeutic windows, predominantly immunosuppressants (N=23, 35.9%) and anti‐infectives (N=21, 32.8%), and there is currently only very limited attention for special populations such as children (N=22, 34.4%). Most studies showed poor methodological quality and a high risk of bias. The lack of external validation and clinical utility evaluation currently limits the further clinical implementation of ML for dose individualization. We therefore have proposed several ways to improve the clinical relevance of the studies and facilitate the translation of ML models into clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%